Salzburg Therapeutics^®

SALZBURG THERAPEUTICS is an innovative drug development company that is developing unique Cytotoxamer^® and Genotoxamer^® products for cancer treatment.    Our technology provides an innovative solution for delivering activated forms of anticancer drugs, nanoparticles, and other moieties specifically to cancer cells.  

The Cytotoxamer^®  approach simultaneously improves efficacy and reduces the toxicities associated with traditional chemotherapy.  The end-result is a longer and a higher quality of life for cancer patients.

The initial focus for product development at Salzburg Therapeutics is a Cytotoxamer^® for the treatment of prostate cancer.

                   Partners

Hutchison Law Group

 Management Team

William Gmeiner, Ph.D., MBA - CSO

Gary Hellmann, Ph.D., MBA - CEO

Scientific Advisory Board

Edward Chu, M.D. Deputy Director      Yale Cancer Center

Yong Chen, Ph.D., Professor, Department of Cancer Biology, Wake Forest University

Waldemar Debinski, M.D., Ph.D. Director, WFUSM Brain Tumor Center of Excellence

Frits Peters, Ph.D., Professor, VU University, Amsterdam 

News

May 2008: Salzburg Therapeutics is announced as a Grand Prize Winner in the PTEN Growth Accelerator Program Competition. 

April 2008: Salzburg Therapeutics is pleased to announce Waldemar Debinski, M.D., Ph.D., Director of the WFUSM Brain Tumor Center of Excellence and Godefridus J. (Frits) Peters, Ph.D., Professor of Medical Oncology at VU University Medical Center, Amsterdam have joined our scientific advisory board. 

March 2008: Salzburg Therapeutics is pleased to announce that Edward Chu, M.D., Deputy Director of the Yale Cancer Center, will serve on our scientific advisory board. 

February 2008: Salzburg Therapeutics submits joint grant proposal with WFU Center for Nanotechnology and Material Science

January 2008: Salzburg Therapeutics joins the WFU Demon Incubator